Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 513295, 20 pages
Review Article

Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis

1Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun 130021, China
2Department of Neurobiology, Care Sciences and Society, Karolinska Institute, 141 86 Stockholm, Sweden

Received 24 August 2014; Revised 1 January 2015; Accepted 1 January 2015

Academic Editor: Fumio Tsuji

Copyright © 2015 Zhong-Xiang Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Multiple sclerosis (MS) is an immune-mediated disorder in the central nervous system (CNS) characterized by inflammation and demyelination as well as axonal and neuronal degeneration. So far effective therapies to reverse the disease are still lacking; most therapeutic drugs can only ameliorate the symptoms or reduce the frequency of relapse. Dendritic cells (DCs) are professional antigen presenting cells (APCs) that are key players in both mediating immune responses and inducing immune tolerance. Increasing evidence indicates that DCs contribute to the pathogenesis of MS and might provide an avenue for therapeutic intervention. Here, we summarize the immunogenic and tolerogenic roles of DCs in MS and review medicinal drugs that may affect functions of DCs and have been applied in clinic for MS treatment. We also describe potential therapeutic molecules that can target DCs by inducing anti-inflammatory cytokines and inhibiting proinflammatory cytokines in MS.